aTyr Pharma Company Culture

Mr. John T. Blake, C.P.A., has been Senior Vice President of Finance at aTyr Pharma, Inc. since February 2017. Mr. Blake has been Vice President of Finance at aTyr Pharma Inc. since October 28, 2015. Mr. Blake served as Principal Accounting Officer at aTyr Pharma Inc. since October 28, 2015 until May 16, 2016. Mr. Blake has served as the Senior Director of Finance and Controller of the aTyr Pharma Inc. since March 2015. Mr. Blake served as the Director of Financial Planning and Analysis of Volcano Corporation from March 2010 to March 2015 and as the SEC Reporting Manager from November 2008 through March 2010. From April 2007 to November 2008, Mr. Blake served in various senior finance roles at Entropic Communications. Prior to 2007, Mr. Blake served as an Auditor in public accounting and an analyst for BD Biosciences. Mr. Blake is a Certified Public Accountant and holds a Bachelor of Business Administration with a concentration in Accountancy from National University.

Dr. Sanuj K. Ravindran, M.D. has been the Chief Business Officer of aTyr Pharma Inc. since January 6, 2016. Dr. Ravindran leads aTyr's corporate development and strategy efforts, including the planning and execution of strategic growth initiatives as its advances its mission to make meaningful medicines for patients with serious diseases. Dr. Ravindran serves as a Consultant at ASIAN Healthcare Fund. Dr. Ravindran served as Vice President of New Business Ventures at The Medicines Company. Dr. Ravindran was a Venture Partner of Asian Healthcare Fund. Dr. Ravindran served as Senior Vice President and Global Head of Corporate Development at The Medicines Company, where he played a key role in the global corporate development, strategic planning and business development activities for acute and intensive care medicine. He served as Managing Director of Asian Healthcare Fund. He was a Principal at Radius Ventures, LLC. He was a Principal at Radius from 2007 to 2010, Dr. Ravindran invested in and assumed Board roles with Ambit Biosciences, Athersys Inc and Resolvyx Pharmaceuticals and worked closely with Biostorage Inc. He served as Head of the India Group at Burrill & Company. He joined Radius Ventures in February 2007. He joined Burrill in July 2003 and was involved with sourcing and evaluating new investment opportunities across the life science spectrum. While with Burrill, Dr. Ravindran played an active role in several investments. He worked in the healthcare investment-banking group at Merrill Lynch, where he assessed financing and M&A candidates for a variety of biotechnology and pharmaceutical clients. He serves on the Advisory Board of RxMD. While with Burrill, he served as a Board Observer at diaDexus, Targanta Therapeutics Corp., and Proventys. He served as a Director of Burrill Venture Capital, Venture Capital Group and Targanta Therapeutics Corp. He serves on the Editorial Board of Biotechnology-Healthcare and is a Senior Scholar at the Jefferson School of Population Health. He is a Board Certified in Internal Medicine and completed his residency training at Jefferson University Hospital. Complementing his clinical experience, he was previously an NCI Research Fellow at Memorial Sloan Kettering Cancer Center and has published work in a variety of clinical disciplines. Dr. Ravindran is also an honorary alumnus of the Indian School of Business in Hyderabad, India. Dr. Ravindran received an M.D. degree from Jefferson Medical College; an M.B.A. from The Kellogg School of Management, where he was a Rothschild Scholar; and a B.A. degree, with honors, from Northwestern University.

Dr. Paul R. Schimmel, Ph.D., serves as Scientific Advisor at KinDex Pharmaceuticals, Inc. Dr. Schimmel has been an Ernest and Jean Hahn Professor of Molecular Biology and Chemistry and has been on the faculty of the Skaggs Institute of Chemical Biology at Scripps Research Institute since 1997. He co-founded Alnylam Pharmaceuticals, Inc. Dr. Schimmel co-founded Sirtris Pharmaceuticals, Inc. He was the John D. and Catherine T. MacArthur Professor of Biophysics and Biochemistry at the Massachusetts Institute of Technology, where he was employed from 1967 to 1997. He is well known for his work in Biophysical Chemistry and Molecular Biology. His field of specialty is the mechanism of action of proteins and the manner in which they act upon the nucleic acids in the cell. He is the Founder of aTyr Pharma, Inc. and Cubist Pharmaceuticals Inc. Dr. Schimmel co-founded Alkermes plc. He co-founded Metabolon, Inc. in 2000. He Co-Founded Repligen Corporation. He serves as the Chairman of Scientific Advisory Board for ActivX Biosciences, Inc. He served as the Chairman of ActivX Biosciences Inc. He served as Co-Chairman of the Board of Repligen Corporation. He has been a Director of Alnylam Pharmaceuticals, Inc. since June 2002 and serves as its Member of the Scientific Advisory Board. He serves as a Director of KinDex Pharmaceuticals, Inc. and Abide Therapeutics, Inc. He has been a Director of Tocagen Inc. since February 25, 2015. He has been a Director of aTyr Pharma Inc. since September 2005. He is a Director of Boragen Inc. He serves as Director of Momenta Pharmaceuticals. He serves as a Member of the Scientific Advisory Board of Illumina, Inc. He serves as a Director and Member of Stragic Advisory Board of Longwood Founders Management, LLC. He served as Member of Scientific Advisory Board at WaferGen Bio-systems, Inc. until February 28, 2017. He served as Member of Scientific Advisory Board at Metabolon, Inc. He served as a Director of Sirtris Pharmaceuticals, Inc. since 2004 and also served as its Member of Scientific Advisory Board. He is a Member of the American Academy of Arts and Sciences. He is a Member of the National Academy of Sciences. He served as a Director of Alkermes plc from 1987 to October 2007. He served as a Director of ActivX Biosciences Inc. He served as a Director of Avicena Group, Inc. from August 1999 to June 12, 2007. He served as Director of Repligen Corporation from March 1981 to September 2007. He also served as the Chairman and Director of Biological Chemistry, American Chemical Society. He received the 1978 ACS/Pfizer award for excellence in enzyme research and was a co-recipient of the Biophysical Society's Emily M. Gray Award for significant contributions to education in biophysics. He is a Author or coauthor of more than 450 scientific papers. He is also a co-author of a widely read three-volume textbook on biophysical chemistry. He has received numerous awards for his contributions to the field. Dr. Schimmel B.A. in biochemistry and biophysics from Ohio Wesleyan University, holds Ph.D. at Cornell University and the Massachusetts Institute of Technology and did Post Doctoral Work at Stanford University.

Xiang-Lei Yang, Ph.D. is the Founder of aTyr Pharma Inc. Xiang-Lei Yang is a leading aminoacyl tRNA synthetase scientist at The Scripps Research Institute.

Nancy Krueger serves as the Vice President, Legal Affairs of aTyr Pharma. Nancy started at aTyr Pharma in Oct of 2014. Nancy currently resides in the Greater San Diego Area.

Jill Broadfoot serves as the Chief Financial Officer of aTyr Pharma. Jill started at aTyr Pharma in July of 2018. Jill currently resides in the Greater San Diego Area.

Ashraf Amanullah serves as the Senior Vice President, Biologics Development and Manufacturing of aTyr Pharma. Ashraf started at aTyr Pharma in February of 2018. Ashraf currently resides in the Greater San Diego Area.